ArticleInternational journal of molecular sciences2020
TLR2 Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation through Decrease in Regulatory T Cells and Impaired IL-10 Production.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Sensory neurons shape γδ T cell effector programs to control Psoriasiform Inflammation.bioRxiv : the preprint server for biology · 2026Article
- Oral microbiota-driven immune modulation along the oral-gut axis: from local signals to systemic inflammation.NPJ biofilms and microbiomes · 2026Review
- A review of core immuno-inflammatory mechanisms and key regulatory targets in psoriasis.American journal of clinical and experimental immunology · 2026Review
- Innovative engineering approaches to model host-microbiome interactions in vitro.Advanced drug delivery reviews · 2025Review
- Exploring the therapeutic potential of aloenin-loaded nanogel for imiquimod-induced psoriasis-like skin conditions: In vitro and in vivo assessment.The Journal of pharmacology and experimental therapeutics · 2025Article
- Immune-related hub genes and their role in psoriasis pathogenesis.Scientific reports · 2025Article
- Elucidating the molecular association and potential mechanisms between psoriasis and atrial fibrillation through biomarker and immune infiltration analysis.Archives of dermatological research · 2025Article
- Pathogenesis of Inflammation in Skin Disease: From Molecular Mechanisms to Pathology.International journal of molecular sciences · 2024Review
- Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.Acta pharmaceutica Sinica. B · 2024Review
- Interactions between toll-like receptors signaling pathway and gut microbiota in host homeostasis.Immunity, inflammation and disease · 2024Review
- Atopic Dermatitis and Psoriasis: Similarities and Differences in Metabolism and Microbiome.Clinical reviews in allergy & immunology · 2024Review
- Pien Tze Huang alleviates Concanavalin A-induced autoimmune hepatitis by regulating intestinal microbiota and memory regulatory T cells.World journal of gastroenterology · 2023Article
- Investigation on the regulatory T cells signature and relevant Foxp3/STAT3 axis in esophageal cancer.Cancer medicine · 2023Article
- Suppression ofInternational journal of molecular sciences · 2022Article
- Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Review
- Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems.Frontiers in immunology · 2021Review
- Role of Toll-Like Receptor 2 in Regulation of T-Helper Immune Response in Chronic Obstructive Pulmonary Disease.Canadian respiratory journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Emerging evidence has demonstrated that Toll-like receptors (TLRs) are associated with autoimmune diseases. In this study, we investigated the role of TLR2 in psoriasis using imiquimod-induced psoriasis-like dermatitis. Although TLR2 signaling is known to play a critical role in the induction of proinflammatory cytokines by immune cells, such as dendritic cells (DCs), macrophages, and monocytes, TLR2 deficiency unexpectedly exacerbated psoriasiform skin inflammation. Importantly, messenger RNA (mRNA) levels of Foxp-3 and IL-10 in the lesional skin were significantly decreased in TLR2 KO mice compared with wild-type mice. Furthermore, flow cytometric analysis of the lymph nodes revealed that the frequency of regulatory T cells (Tregs) among CD4-positive cells was decreased. Notably, stimulation with Pam3CSK4 (TLR2/1 ligand) or Pam2CSK4 (TLR2/6 ligand) increased IL-10 production from Tregs and DCs and the proliferation of Tregs. Finally, adoptive transfer of Tregs from wild-type mice reduced imiquimod-induced skin inflammation in TLR2 KO mice. Taken together, our results suggest that TLR2 signaling directly enhances Treg proliferation and IL-10 production by Tregs and DCs, suppressing imiquimod-induced psoriasis-like skin inflammation. Enhancement of TLR2 signaling may be a new therapeutic strategy for psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.